Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 109

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 109
---
</div>

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Research and development expenses

Research and development
expenses decreased by approximately $2,880 thousand or 357.3%, to approximately income of $2,074 thousand for the year ended December
31, 2024, compared to $806 thousand for the year ended December 31, 2023. The decrease resulted mainly from the Horizon 2020 Grant, and
from a decrease in subcontractors’ expenses due to lower research and development activity during 2024.

General and administrative expenses

General and administrative
expenses decreased by approximately $413 thousand, or 36.7%, to approximately $712 thousand for the year ended December 31, 2024, compared
to approximately $1,125 thousand for the year ended December 31, 2023. The decrease resulted mainly from an decrease in professional
fees due to the recognition of prepaid issuance costs associated with the former initial public offering process, recognized as expense
following the entry into the business combination agreement, or BCA, with OceanTech Corp. during the second quarter of 2023 and additional
expenses associated with the BCA.

Finance income (expense)

Finance expenses decreased
by approximately $6,070 thousand, or 275.8%, to approximately $3,869 thousand finance income for the year ended December 31, 2024, compared
to approximately $2,201 thousand finance expense for the year ended December 31, 2023. The decrease resulted mainly from change in fair
value of convertible notes and a change in fair value of warrant liability.

Net income (loss)

Net loss decreased by
approximately $9,363 thousand to approximately $5,231 thousand net income for the year ended December 31, 2024, compared to $4,132
thousand net loss for the year ended December 31, 2023. The decrease was mainly the result of an increase in our finance income and
from the Horizon 2020 Grant.

Critical Accounting Policies and Estimates

We describe our significant accounting policies and estimates in Note 2
to our annual financial statements contained elsewhere in this prospectus. We believe that these accounting policies and estimates are
critical in order to fully understand and evaluate our financial condition and results of operations.

We prepare our financial statements
in accordance with U.S. GAAP.

In preparing these financial
statements, management has made judgments, estimates and assumptions that affect